Almost half of FA patients with MDS or AML exhibit this genomic abnormality that leads to a >10-fold increase of the EVI1 transcript and constitutes an adverse risk factor.94–97 In contrast, gain of 3q is a very rare event in non-FA patients. This evidence concerns the gene RUNX1 and acute myeloid leukemia.